DPP4

DPP4

A gene on chromosome 2q24.3 that encodes dipeptidyl-peptidase 4, a ubiquitous, membrane-bound enzyme with roles in nutrition, metabolism, the endocrine system, immune regulation (for instance, it is essential for T-cell receptor (TCR)-mediated T-cell activation), bone marrow mobilisation, apoptosis, cell adhesion and tumourigenesis.
References in periodicals archive ?
Interestingly, DPP4 inhibitors (gliptins), one of the newer medication classes have the highest rates of adherence, with only 10 to 20 percent of medication doses not taken.
DEVELOPMENT: The team led by CSIR-IICB's Partha Chakrabarti identified the contribution of a particular class of white blood cells called T lymphocytes (Th17) behind the aberrant abundance of DPP4 in diabetics.
He has led clinical development of multiple compounds in the Metabolic and Diabetes therapeutic areas, including DPP4 and SGLT2 inhibitors, GLP-1 agonists, leptin and prandial insulins among others.
Comparison of the DPP4 nucleotide sequences of humans, dromedary camels, and domestic pigs showed that the porcine DPP4 is identical to the dromedary camel DPP4 at the 14 aa positions that have been shown to determine species tropism (Table) (8,9).
The targeted mRNAs of has-miR-429 and has-miR-5088, DPP4, SERPING1, and AQP3 were validated to be downregulated in the new RIF samples in our previous report.
Keywords: Alpha-glucosidase inhibitors, DPP4 inhibitors, GLP1 receptor agonists, Metformin, Pioglitazone, Pramlintide, SGLT2 inhibitors.
To prevent hypoglycemia and weight gain in diabetics, the newer classes of drugs like the DPP4 (dipeptidyl peptidase-4) inhibitors, GLP-1 (glucagon-like peptide-1), and the SGLT2 (sodium glucose cotransporter-2) are preferred.
The receptor DPP4 is important in the infection of a non-permissive cell line where DPP4 has diverse functions in homeostasis, neurotransmitter function and modulation of cardiac signaling.
Abstract # 2016-A-2067-Diabetes: Comparison of Alogliptin/Pioglitazone Fixed Dose Combination (APC) with DPP4 Inhibitor Monotherapy in Reducing HbA1c (Szymanki K.
Prevention of obesity-induced renal injury in male mice by DPP4 inhibition," Endocrinology, vol.
1), with significantly elevated risk also seen when compared with DPP4 inhibitors (HR, 4.
5,7,13,14) On the other hand, diabetes mellitus is possibly associated with a decreased risk because diabetic patients appear to have increased DPP4 activity to aid in the breakdown of substance P.